Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 63
Summary
- Conditions
- Esophageal Adenocarcinoma
- Gastric Adenocarcinoma
- HER-2 Gene Amplification
- Metastasis
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03783936
- Collaborators
- EMD Serono
- University of North Carolina, Chapel Hill
- Investigators
- Principal Investigator: Autumn McRee, MD University of North Carolina, Chapel Hill
Get Well Soon